In addition to NK cell-mediated tumor cell killing, we analyzed the capacity of these DuoBody variants to trigger immunomodulatory interferon-γ (IFN-γ) and tumor necrosis factor α (TNF-α) cytokine release (Figures 4C and 4D). Here, IFNG is linked to neoplasm.